Skip to content

GLUCOSAMINE/CHONDROITIN and PHYSICAL THERAPY EFFECTS ON OLDER POPULATION WITH KNEE OSTEOARTHRITIS

EFFECTS OF COMBINED GLUCOSAMINE/CHONDROITIN WITH STRUCTURED PHYSICAL THERAPY PROGRAM ON KNEE OSTEOARTHRITIS: A RANDOMIZED CONTROL TRAIL

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05321836
Enrollment
30
Registered
2022-04-11
Start date
2021-07-26
Completion date
2022-03-25
Last updated
2022-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Keywords

OA, Chondratin sulfate, glucosamine, Physiotherapy

Brief summary

to see the effect of glucosamine chondratin sulfate with and without physiotherapy in knee osteoarthritis

Detailed description

it is a randomized control trail to evaluate the effectiveness of glucosamine chondratin sulfate alone and in combination with physiotherapy on knee osteoarthritis

Interventions

control group

COMBINATION_PRODUCTglucosamine chondritin & Physiotherapy

experimental group

Sponsors

Muhammad salman, PT
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

two groups

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* age \> 50 years with radiographic evidence of mild to moderate knee OA (Kellgren Lawrence grade II & III 20) who met the ACR clinical 21, * radiographic classification criteria or confirmation of mild to moderate radiographic evidence of knee OA from a personal physician * not currently participating in another intervention study

Exclusion criteria

* dementia (Mini-Mental State Examination \[MMSE\]\< 24) * active cancer other than skin cancer * anemia (participants with an hematocrit (HCT)\< 32 (or a hemoglobin below10) were excluded due to possible inability to adequately exercise or the increased potential for increased risk for serious adverse cardiovascular events) * severe renal insufficiency (serum creat\> 2) * hepatic disease

Design outcomes

Primary

MeasureTime frameDescription
WOMAC6 monthshigher score means worst patient condition and lower score means better

Secondary

MeasureTime frameDescription
SF-366 monthshigher score means better patient condition and lower score means worst

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026